In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

There's another $215 million tied to the achievement of regulatory and sales-based milestones with LNG-451, a compound that targets tumours with EGFR exon 20 mutations. It's a big deal for ...

Johnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...

Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as of ...

Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million ...

Patients harboring EGFR mutations initially respond well to EGFR–TKIs, but acquired mutations render the patients resistant to the available drugs. These mutations include EGFR T790M point mutation.

Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommendation from the EMA’s Human ...

with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations. These mutations are identified by an FDA-approved test in patients. Sunvozertinib, an irreversible EGFR ...

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference ...